Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
PREMARIN |
| Manufacturer |
|
Wyeth Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Conjugated estrogens 0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg; tabs. |
| Also |
|
• PREMARIN VAGINAL CREAM
|
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Vulvar and vaginal atrophy. Osteoporosis prevention (consider alternative treatments). Hypoestrogenism. |
| Children |
|
Not applicable. |
| Adults |
|
Menopausal symptoms or vaginal atrophy: 0.3mg/day. Osteoporosis: 0.3mg/day; supplement diet with calcium 1.5g/day and Vit. D 400–800IU/day. Give cyclically (3 weeks on, 1 week off) or continuously. Hypoestrogenism due to hypogonadism, castration, ovarian failure: 0.3–0.625mg/day, given cyclically (3 weeks on, 1 week off). Female castration, ovarian failure: 1.25mg/day, cyclically. For all: adjust as needed; periodically reassess need if dose is increased. |
| Contraindications |
|
Breast or estrogen-dependent carcinoma, unless palliative. Undiagnosed abnormal genital bleeding. Pulmonary embolism/DVT (active or history of). Arterial thromboembolism (eg, stroke, MI; active or recent). Pregnancy (Cat.X). |
| Precautions |
|
Not for prevention of cardiovascular disease. Use for shortest duration consistent with treatment goals and risks. Reevaluate periodically. Patients with an intact uterus should almost always receive a progestin with systemic estrogens to avoid endometrial hyperplasia. Discontinue if cardiovascular events occur or are suspected; if jaundice occurs; and during immobilization or at least 2 weeks before surgery associated with thromboembolism. Hepatic dysfunction. Conditions aggravated by fluid retention. Gallbladder disease. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include BP, mammogram, PAP smear). Adolescents. Nursing mothers: not recommended. |
| Adverse Reactions |
|
See literature. Increased risk of cardiovascular events, estrogen-dependent carcinoma, gallbladder disease, thromboembolic disorders, hepatic tumors. GI upset, breakthrough bleeding, edema, weight changes, mastodynia, hypertension, depression, intolerance to contact lenses. |
| How Supplied |
Tabs 0.3mg, 0.625mg, 1.25mg—100, 1000
0.45mg, 0.9mg—100
Cream—42.5g (w. applicator) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
